On April 15, 2018, the Board of Directors of Axsome Therapeutics, Inc. appointed Nick Pizzie, CPA, MBA, as Chief Financial Officer of the Company, effective May 16, 2018 (the effective date), to serve until such time as his removal or resignation. Mr. Pizzie, age 43, was the Vice President and Chief Financial Officer of Pierre Fabre USA, the U.S. affiliate of Pierre Fabre, prior to joining the Company. Previously, he was Senior Finance Director at Immucor.

Prior to Immucor, he held positions of increasing responsibility in finance and accounting at Merck and Pfizer. Mr. Pizzie began his career at Arthur Andersen, where he served as staff auditor. On April 13, 2018, the company received a resignation letter from John Golubieski, Chief Financial Officer of the Company, effective May 9, 2018.

On the effective date, Mr. Pizzie will assume responsibility as the Company's principal financial officer and principal accounting officer. To ensure that there is continuity in the Company's principal officers for the interim period between Mr. Golubieski's resignation and the effective date, and in the event of an earlier departure by Mr. Golubieski, the board has also designated Herriot Tabuteau, M.D., the company's chief executive officer, as the company's interim principal financial officer and Joseph Debrah-Afful, CPA, MBA, the company's director of finance, as the company's interim principal accounting officer.